{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:12:32Z","timestamp":1761919952724},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s11920-015-0570-4","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T04:53:23Z","timestamp":1426481603000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Neurology Issues in Schizophrenia"],"prefix":"10.1007","volume":"17","author":[{"given":"Katharina","family":"H\u00fcfner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Frajo-Apor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,17]]},"reference":[{"issue":"11","key":"570_CR1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1176\/appi.ajp.2013.12091148","volume":"170","author":"W Ren","year":"2013","unstructured":"Ren W, Lui S, Deng W, Li F, Li M, Huang X, et al. Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia. Am J Psychiatry. 2013;170(11):1308\u201316.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"570_CR2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1469-7610.2011.02475.x","volume":"53","author":"M Mayoral","year":"2012","unstructured":"Mayoral M, Bombin I, Castro-Fornieles J, Gonzalez-Pinto A, Otero S, Parellada M, et al. Longitudinal study of neurological soft signs in first-episode early-onset psychosis. J Child Psychol Psychiatr allied Discip. 2012;53(3):323\u201331.","journal-title":"J Child Psychol Psychiatr allied Discip"},{"key":"570_CR3","doi-asserted-by":"crossref","unstructured":"Gay O, Plaze M, Oppenheim C, Mouchet-Mages S, Gaillard R, Olie JP, et al. Cortex morphology in first-episode psychosis patients with neurological soft signs. Schizophr Bull. 2013;39(4):820\u20139. This study investigated the cortical sulcation, as a potential marker for neurodevelopmental deviation, in 44 patients with first onset psychosis. Reductions of cortical sulcation in both hemispheres were found in patients with neurological soft signs as compared to those with non-significant NSS.","DOI":"10.1093\/schbul\/sbs083"},{"issue":"1","key":"570_CR4","first-page":"5","volume":"48","author":"O Kaluzynska","year":"2014","unstructured":"Kaluzynska O, Rabe-Jablonska J. Neurological soft signs as a candidate for endophenotype of schizophrenia. Psychiatr Pol. 2014;48(1):5\u201318.","journal-title":"Psychiatr Pol"},{"issue":"3","key":"570_CR5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/schbul\/sbt063","volume":"40","author":"Q Zhao","year":"2014","unstructured":"Zhao Q, Li Z, Huang J, Yan C, Dazzan P, Pantelis C, et al. Neurological soft signs are not \"soft\" in brain structure and functional networks: evidence from ALE meta-analysis. Schizophr Bull. 2014;40(3):626\u201341. This metanalysis of 6 structural and 15 functional magnetic resonance imaging studies provides evidence for significant and localized changes in brain structure and function associated with specific neurological soft signs. The study thus does away with the conventional believ that neurological soft signs cannot be attributed to specific brain regions.","journal-title":"Schizophr Bull"},{"issue":"3","key":"570_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0165-1781(89)90148-0","volume":"27","author":"RW Buchanan","year":"1989","unstructured":"Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 1989;27(3):335\u201350.","journal-title":"Psychiatry Res"},{"issue":"2","key":"570_CR7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-1781(95)02535-2","volume":"56","author":"EY Chen","year":"1995","unstructured":"Chen EY, Shapleske J, Luque R, McKenna PJ, Hodges JR, Calloway SP, et al. The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res. 1995;56(2):183\u2013204.","journal-title":"Psychiatry Res"},{"issue":"1","key":"570_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.schres.2011.09.015","volume":"134","author":"L Kong","year":"2012","unstructured":"Kong L, Bachmann S, Thomann PA, Essig M, Schroder J. Neurological soft signs and gray matter changes: a longitudinal analysis in first-episode schizophrenia. Schizophr Res. 2012;134(1):27\u201332.","journal-title":"Schizophr Res"},{"issue":"2","key":"570_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000350999","volume":"68","author":"D Hirjak","year":"2013","unstructured":"Hirjak D, Wolf RC, Stieltjes B, Hauser T, Seidl U, Thiemann U, et al. Neurological soft signs and brainstem morphology in first-episode schizophrenia. Neuropsychobiology. 2013;68(2):91\u20139.","journal-title":"Neuropsychobiology"},{"issue":"2","key":"570_CR10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10548-013-0292-z","volume":"27","author":"D Hirjak","year":"2014","unstructured":"Hirjak D, Wolf RC, Stieltjes B, Hauser T, Seidl U, Schroder J, et al. Cortical signature of neurological soft signs in recent onset schizophrenia. Brain Topogr. 2014;27(2):296\u2013306.","journal-title":"Brain Topogr"},{"issue":"4","key":"570_CR11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpsychires.2012.01.015","volume":"46","author":"D Hirjak","year":"2012","unstructured":"Hirjak D, Wolf RC, Stieltjes B, Seidl U, Schroder J, Thomann PA. Neurological soft signs and subcortical brain morphology in recent onset schizophrenia. J Psychiatr Res. 2012;46(4):533\u20139.","journal-title":"J Psychiatr Res"},{"issue":"2\u20133","key":"570_CR12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.psychres.2012.03.008","volume":"200","author":"R Prikryl","year":"2012","unstructured":"Prikryl R, Ceskova E, Tronerova S, Kasparek T, Kucerova HP, Ustohal L, et al. Dynamics of neurological soft signs and its relationship to clinical course in patients with first-episode schizophrenia. Psychiatry Res. 2012;200(2\u20133):67\u201372.","journal-title":"Psychiatry Res"},{"key":"570_CR13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pnpbp.2012.12.006","volume":"43","author":"Q Zhao","year":"2013","unstructured":"Zhao Q, Ma YT, Lui SS, Liu WH, Xu T, Yu X, et al. Neurological soft signs discriminate schizophrenia from major depression but not bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;43:72\u20138.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"570_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.pra.0000445250.20875.0e","volume":"20","author":"S Rigucci","year":"2014","unstructured":"Rigucci S, Dimitri-Valente G, Mandarelli G, Manfredi G, Comparelli A, De Filippis S, et al. Neurological soft signs discriminate schizophrenia from bipolar disorder. J Psychiatr Pract. 2014;20(2):147\u201353.","journal-title":"J Psychiatr Pract"},{"issue":"1\u20132","key":"570_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.psychres.2014.04.014","volume":"218","author":"S Romeo","year":"2014","unstructured":"Romeo S, Chiandetti A, Siracusano A, Troisi A. An exploratory study of the relationship between neurological soft signs and theory of mind deficits in schizophrenia. Psychiatry Res. 2014;218(1\u20132):7\u201311.","journal-title":"Psychiatry Res"},{"issue":"1","key":"570_CR16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/schbul\/sbt049","volume":"40","author":"PJ Moberg","year":"2014","unstructured":"Moberg PJ, Kamath V, Marchetto DM, Calkins ME, Doty RL, Hahn CG, et al. Meta-analysis of olfactory function in schizophrenia, first-degree family members, and youths at-risk for psychosis. Schizophr Bull. 2014;40(1):50\u20139.","journal-title":"Schizophr Bull"},{"issue":"1\u20133","key":"570_CR17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2011.12.005","volume":"135","author":"AS Cohen","year":"2012","unstructured":"Cohen AS, Brown LA, Auster TL. Olfaction, \"olfiction,\" and the schizophrenia-spectrum: an updated meta-analysis on identification and acuity. Schizophr Res. 2012;135(1\u20133):152\u20137.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"570_CR18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.schres.2012.04.016","volume":"139","author":"BI Turetsky","year":"2012","unstructured":"Turetsky BI, Kamath V, Calkins ME, Brewer WJ, Wood SJ, Pantelis C, et al. Olfaction and schizophrenia clinical risk status: just the facts. Schizophr Res. 2012;139(1\u20133):260\u20131. author reply 2\u20133. This critical commentary discusses the findings from the Cohen et al. 2012 metanalysis and advocates olfactory impairment as a possible biomarker of schizophrenia.","journal-title":"Schizophr Res"},{"issue":"1","key":"570_CR19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/schbul\/sbr050","volume":"39","author":"V Kamath","year":"2013","unstructured":"Kamath V, Moberg PJ, Kohler CG, Gur RE, Turetsky BI. Odor hedonic capacity and anhedonia in schizophrenia and unaffected first-degree relatives of schizophrenia patients. Schizophr Bull. 2013;39(1):59\u201367.","journal-title":"Schizophr Bull"},{"issue":"11","key":"570_CR20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jpsychires.2013.07.014","volume":"47","author":"V Kamath","year":"2013","unstructured":"Kamath V, Turetsky BI, Calkins ME, Bilker WB, Frishberg N, Borgmann-Winter K, et al. The effect of odor valence on olfactory performance in schizophrenia patients, unaffected relatives and at-risk youth. J Psychiatr Res. 2013;47(11):1636\u201341.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"570_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.psychres.2012.09.052","volume":"208","author":"M Clepce","year":"2013","unstructured":"Clepce M, Reich K, Gossler A, Kornhuber J, Thuerauf N. Olfactory perception in schizophrenia: the rating range for hedonic judgements is increased during acute episodes. Psychiatry Res. 2013;208(1):81\u20133.","journal-title":"Psychiatry Res"},{"key":"570_CR22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1471-244X-13-218","volume":"13","author":"A Kastner","year":"2013","unstructured":"Kastner A, Malzahn D, Begemann M, Hilmes C, Bickeboller H, Ehrenreich H. Odor naming and interpretation performance in 881 schizophrenia subjects: association with clinical parameters. BMC Psychiatr. 2013;13:218.","journal-title":"BMC Psychiatr"},{"issue":"3","key":"570_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/15622975.2011.615862","volume":"15","author":"V Kamath","year":"2014","unstructured":"Kamath V, Turetsky BI, Calkins ME, Kohler CG, Conroy CG, Borgmann-Winter K, et al. Olfactory processing in schizophrenia, non-ill first-degree family members, and young people at-risk for psychosis. World J Biol Psychiatr : Off J World Fed Soc Biol Psychiatr. 2014;15(3):209\u201318.","journal-title":"World J Biol Psychiatr : Off J World Fed Soc Biol Psychiatr"},{"key":"570_CR24","doi-asserted-by":"crossref","unstructured":"Gill KE, Evans E, Kayser J, Ben-David S, Messinger J, Bruder G, et al. Smell identification in individuals at clinical high risk for schizophrenia. Psychiatry research. 2014.","DOI":"10.1016\/j.psychres.2014.07.018"},{"key":"570_CR25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-14-75","volume":"14","author":"MJ Clancy","year":"2014","unstructured":"Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatr. 2014;14:75.","journal-title":"BMC Psychiatr"},{"issue":"9","key":"570_CR26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2012.01.011","volume":"71","author":"MC Clarke","year":"2012","unstructured":"Clarke MC, Tanskanen A, Huttunen MO, Clancy M, Cotter DR, Cannon M. Evidence for shared susceptibility to epilepsy and psychosis: a population-based family study. Biol Psychiatry. 2012;71(9):836\u20139.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"570_CR27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00406-013-0436-x","volume":"264","author":"D Schoepf","year":"2014","unstructured":"Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci. 2014;264(1):3\u201328.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"570_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2012.02.013","volume":"138","author":"KY Tsai","year":"2012","unstructured":"Tsai KY, Lee CC, Chou YM, Su CY, Chou FH. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr Res. 2012;138(1):41\u20137.","journal-title":"Schizophr Res"},{"issue":"3","key":"570_CR29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijcard.2014.03.101","volume":"173","author":"M Li","year":"2014","unstructured":"Li M, Fan YL, Tang ZY, Cheng XS. Schizophrenia and risk of stroke: a meta-analysis of cohort studies. Int J Cardiol. 2014;173(3):588\u201390.","journal-title":"Int J Cardiol"},{"issue":"1\u20133","key":"570_CR30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2010.12.007","volume":"126","author":"CH Liao","year":"2011","unstructured":"Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, Lane HY, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126(1\u20133):110\u20136.","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"570_CR31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.schres.2013.08.029","volume":"150","author":"J Sweeting","year":"2013","unstructured":"Sweeting J, Duflou J, Semsarian C. Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. Schizophr Res. 2013;150(2\u20133):398\u2013403.","journal-title":"Schizophr Res"},{"issue":"1","key":"570_CR32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.psychres.2013.10.020","volume":"215","author":"AA Phillips","year":"2014","unstructured":"Phillips AA, Warburton DE, Flynn SW, Fredrikson D, Lang DJ. Assessment of arterial stiffness among schizophrenia-spectrum disorders using aortic pulse wave velocity and arterial compliance: a pilot study. Psychiatry Res. 2014;215(1):14\u20139.","journal-title":"Psychiatry Res"},{"key":"570_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2377-13-16","volume":"13","author":"RA Marrie","year":"2013","unstructured":"Marrie RA, Fisk JD, Yu BN, Leung S, Elliott L, Caetano P, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol. 2013;13:16.","journal-title":"BMC Neurol"},{"key":"570_CR34","doi-asserted-by":"crossref","unstructured":"Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophrenia research. 2014.","DOI":"10.1016\/j.schres.2014.04.041"},{"key":"570_CR35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/B978-0-7020-4086-3.00030-8","volume":"119","author":"JY Streifler","year":"2014","unstructured":"Streifler JY, Molad Y. Connective tissue disorders: systemic lupus erythematosus, Sjogren\u2019s syndrome, and scleroderma. Handb Clin Neurol. 2014;119:463\u201373.","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"570_CR36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.smrv.2012.10.003","volume":"17","author":"MJ Kalucy","year":"2013","unstructured":"Kalucy MJ, Grunstein R, Lambert T, Glozier N. Obstructive sleep apnoea and schizophrenia\u2014a research agenda. Sleep Med Rev. 2013;17(5):357\u201365.","journal-title":"Sleep Med Rev"},{"key":"570_CR37","doi-asserted-by":"crossref","unstructured":"Annamalai A, Palmese LB, Chwastiak LA, Srihari VH, Tek C. High rates of obstructive sleep apnea symptoms among patients with schizophrenia. Psychosomatics. 2014.","DOI":"10.1016\/j.psym.2014.02.009"},{"issue":"9","key":"570_CR38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","volume":"70","author":"MS Kayser","year":"2013","unstructured":"Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133\u20139. Observational cohort study to investigate the frequency of isolated psychiatric symptoms in patients with NMDA-r encephalitis. These symptoms can occur at the time of initial diagnosis or at relapse. Pratical recommendations are given.","journal-title":"JAMA Neurol"},{"issue":"8","key":"570_CR39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3109\/15563650.2013.829235","volume":"51","author":"M Punja","year":"2013","unstructured":"Punja M, Pomerleau AC, Devlin JJ, Morgan BW, Schier JG, Schwartz MD. Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: an etiology worth considering in the differential diagnosis of delirium. Clin Toxicol. 2013;51(8):794\u20137.","journal-title":"Clin Toxicol"},{"issue":"3","key":"570_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/2013.jamapsychiatry.86","volume":"70","author":"J Steiner","year":"2013","unstructured":"Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatr. 2013;70(3):271\u20138.","journal-title":"JAMA Psychiatr"},{"key":"570_CR41","doi-asserted-by":"crossref","unstructured":"Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Molecular psychiatry. 2013.","DOI":"10.1038\/mp.2013.110"},{"issue":"12","key":"570_CR42","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1017\/S003329171300295X","volume":"44","author":"TA Pollak","year":"2014","unstructured":"Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med. 2014;44(12):2475\u201387.","journal-title":"Psychol Med"},{"key":"570_CR43","doi-asserted-by":"crossref","unstructured":"Pearlman DM, Najjar S. Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophrenia research. 2014.","DOI":"10.1016\/j.schres.2014.05.001"},{"key":"570_CR44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.physbeh.2014.04.038","volume":"131","author":"Z Vukadinovic","year":"2014","unstructured":"Vukadinovic Z. NMDA receptor hypofunction and the thalamus in schizophrenia. Physiol Behav. 2014;131:156\u20139.","journal-title":"Physiol Behav"},{"issue":"1","key":"570_CR45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.24189","volume":"76","author":"L Dahm","year":"2014","unstructured":"Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76(1):82\u201394.","journal-title":"Ann Neurol"},{"key":"570_CR46","doi-asserted-by":"crossref","unstructured":"Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014. An important evaluation of antipsychotic-induced EPS in first episode schizophrenia.","DOI":"10.1016\/j.euroneuro.2014.07.001"},{"issue":"5","key":"570_CR47","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","volume":"81","author":"R Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463\u20139. Very good overview on evidence levels of treatment approaches for tardive syndromes.","journal-title":"Neurology"},{"issue":"1","key":"570_CR48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/acps.12241","volume":"130","author":"P Ifteni","year":"2014","unstructured":"Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand. 2014;130(1):25\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"570_CR49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JCP.0b013e3182900dfe","volume":"33","author":"PH Hsieh","year":"2013","unstructured":"Hsieh PH, Hsiao FY, Gau SS, Gau CS. Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol. 2013;33(3):299\u2013305.","journal-title":"J Clin Psychopharmacol"},{"key":"570_CR50","doi-asserted-by":"crossref","unstructured":"Elmorsy E, Elzalabany LM, Elsheikha HM, Smith PA. Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood brain barrier. Brain research. 2014.","DOI":"10.1016\/j.brainres.2014.08.011"},{"issue":"1","key":"570_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.09.006","volume":"72","author":"MF Green","year":"2004","unstructured":"Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004;72(1):1\u20133.","journal-title":"Schizophr Res"},{"issue":"6","key":"570_CR52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","volume":"38","author":"JA Lieberman","year":"2013","unstructured":"Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38(6):968\u201375.","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"570_CR53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2013.05.023","volume":"148","author":"SI Deutsch","year":"2013","unstructured":"Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophr Res. 2013;148(1\u20133):138\u201344.","journal-title":"Schizophr Res"},{"key":"570_CR54","doi-asserted-by":"crossref","unstructured":"Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70(12):1267\u201375. Interesting novel therapeutic approach in schizophrenia treatment \u2013 for both, neurocognitive functions and clinical symptoms.","DOI":"10.1001\/jamapsychiatry.2013.2159"},{"issue":"2\u20133","key":"570_CR55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","volume":"134","author":"DL Boggs","year":"2012","unstructured":"Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J, et al. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res. 2012;134(2\u20133):207\u201310.","journal-title":"Schizophr Res"},{"issue":"11","key":"570_CR56","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.euroneuro.2013.08.003","volume":"23","author":"PD Harvey","year":"2013","unstructured":"Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol : J Eur Coll Neuropsychopharmacol. 2013;23(11):1373\u201382.","journal-title":"Eur Neuropsychopharmacol : J Eur Coll Neuropsychopharmacol"},{"issue":"5","key":"570_CR57","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","volume":"168","author":"T Wykes","year":"2011","unstructured":"Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472\u201385.","journal-title":"Am J Psychiatry"},{"key":"570_CR58","doi-asserted-by":"crossref","unstructured":"Fisher M, Loewy R, Carter C, Lee A, Ragland JD, Niendam T, et al. Neuroplasticity-Based Auditory Training Via Laptop Computer Improves Cognition in Young Individuals With Recent Onset Schizophrenia. Schizophr Bull. 2014.","DOI":"10.1093\/schbul\/sbt232"},{"issue":"2\u20133","key":"570_CR59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.schres.2013.08.025","volume":"150","author":"G Garrido","year":"2013","unstructured":"Garrido G, Barrios M, Penades R, Enriquez M, Garolera M, Aragay N, et al. Computer-assisted cognitive remediation therapy: cognition, self-esteem and quality of life in schizophrenia. Schizophr Res. 2013;150(2\u20133):563\u20139.","journal-title":"Schizophr Res"},{"key":"570_CR60","doi-asserted-by":"crossref","unstructured":"Trapp W, Landgrebe M, Hoesl K, Lautenbacher S, Gallhofer B, Gunther W, et al. Cognitive remediation improves cognition and good cognitive performance increases time to relapse\u2014results of a 5\u00a0year catamnestic study in schizophrenia patients. BMC Psychiatr. 2013;13:184.","DOI":"10.1186\/1471-244X-13-184"},{"issue":"3","key":"570_CR61","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/schbul\/sbt057","volume":"40","author":"P Sanchez","year":"2014","unstructured":"Sanchez P, Pena J, Bengoetxea E, Ojeda N, Elizagarate E, Ezcurra J, et al. Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial. Schizophr Bull. 2014;40(3):707\u201315.","journal-title":"Schizophr Bull"},{"issue":"3","key":"570_CR62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/schbul\/sbs120","volume":"39","author":"JP Lindenmayer","year":"2013","unstructured":"Lindenmayer JP, McGurk SR, Khan A, Kaushik S, Thanju A, Hoffman L, et al. Improving social cognition in schizophrenia: a pilot intervention combining computerized social cognition training with cognitive remediation. Schizophr Bull. 2013;39(3):507\u201317. Interesting publication on the benefits of a combination of neurocognitive and social cogntive training.","journal-title":"Schizophr Bull"},{"issue":"6","key":"570_CR63","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1017\/S0033291710001765","volume":"41","author":"SM Eack","year":"2011","unstructured":"Eack SM, Pogue-Geile MF, Greenwald DP, Hogarty SS, Keshavan MS. Mechanisms of functional improvement in a 2-year trial of cognitive enhancement therapy for early schizophrenia. Psychol Med. 2011;41(6):1253\u201361.","journal-title":"Psychol Med"},{"issue":"1","key":"570_CR64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/eip.12029","volume":"8","author":"CR Bowie","year":"2014","unstructured":"Bowie CR, Grossman M, Gupta M, Oyewumi LK, Harvey PD. Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long-term course of illness. Early Interv Psychiatr. 2014;8(1):32\u20138.","journal-title":"Early Interv Psychiatr"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-015-0570-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-015-0570-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-015-0570-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T01:00:16Z","timestamp":1566435616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-015-0570-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,17]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s11920-015-0570-4","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,17]]},"article-number":"32"}}